The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 21, 2025

Filed:

Sep. 12, 2019
Applicants:

The Board of Regents of the University of Texas System, Austin, TX (US);

Immune-onc Therapeutics, Inc., Palo Alto, CA (US);

Inventors:

Zhiqiang An, Houston, TX (US);

Chengcheng Zhang, Dallas, TX (US);

Ningyan Zhang, Houston, TX (US);

Xun Gui, Houston, TX (US);

Mi Deng, Dallas, TX (US);

Tao Huang, Palo Alto, CA (US);

Qiang Liu, Palo Alto, CA (US);

X. Charlene Liao, Palo Alto, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01); A61K 51/10 (2006.01); A61P 35/02 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/6849 (2017.08); A61K 47/6867 (2017.08); A61K 47/6913 (2017.08); A61K 51/1027 (2013.01); A61K 51/1069 (2013.01); A61P 35/02 (2018.01); G01N 33/57426 (2013.01); G01N 33/57492 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.


Find Patent Forward Citations

Loading…